(Newser)
–
Think studies of new drugs in the New England Journal of Medicine are unassailable? Experts are beginning to wonder, because pharmaceutical companies pay academics to conduct many of those studies—and the approval of high-profile drugs like Vioxx, Avandia, and Celebrex has led to thousands...
Read full story »
